Cencora, Inc. $COR Holdings Increased by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its stake in Cencora, Inc. (NYSE:COR) by 54.8% in the third quarter, HoldingsChannel reports. The fund owned 18,187 shares of the company’s stock after purchasing an additional 6,442 shares during the quarter. Public Sector Pension Investment Board’s holdings in Cencora were worth $5,684,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Cloud Capital Management LLC acquired a new position in shares of Cencora during the 3rd quarter valued at $31,000. Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares in the last quarter. Westside Investment Management Inc. grew its holdings in Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares during the period. Copia Wealth Management raised its position in Cencora by 505.0% in the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after acquiring an additional 101 shares in the last quarter. Finally, Caldwell Trust Co acquired a new stake in Cencora in the 2nd quarter valued at about $46,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on COR shares. Barclays raised their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Robert W. Baird set a $415.00 target price on Cencora in a research report on Tuesday, January 13th. Bank of America reduced their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Finally, Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The MWI–Covetrus merger values Cencora’s animal-health unit at ~$3.5B, providing proceeds and a clearer strategic focus on drug distribution — investors see this as de-risking and simplifying the company. Reuters: Cencora’s animal health unit to merge with Covetrus Philadelphia Business Journal: Cencora makes $3.5B deal
• Positive Sentiment: Coverage highlights that the divestiture lets Cencora refocus capital and management on higher-margin, core drug distribution operations — a narrative that can support multiple expansion. MSN: Cencora to refocus on drug distribution
• Neutral Sentiment: Analysts currently rate Cencora around a “moderate buy,” so the market reaction may be in line with expectations rather than a surprise re-rating. American Banking News: Consensus Moderate Buy
• Neutral Sentiment: Options activity suggests some traders are positioning for bigger moves, which can increase short-term volatility but doesn’t change fundamentals. Zacks: Options market activity
• Negative Sentiment: The deal reduces diversification and recurring revenue from animal health; proceeds may be one-time and the company still faces high leverage and integration/execution risk if transaction terms are complex. TMCNet: Covetrus and MWI Animal Health to Merge

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 15,220 shares of company stock worth $5,282,867 in the last quarter. 0.38% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of Cencora stock opened at $360.50 on Thursday. The stock has a market cap of $70.13 billion, a PE ratio of 43.33, a price-to-earnings-growth ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a 12 month low of $240.10 and a 12 month high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The business has a fifty day simple moving average of $348.82 and a 200-day simple moving average of $330.12.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the prior year, the business earned $3.73 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.